Vedanta Biosciences Appoints Troy Ignelzi, Chief Financial Officer at Karuna Therapeutics, to Its Board of Directors. Prior to joining Sanofi, he spent over 20 years with GlaxoSmithKline in Germany, Canada, France and, latterly, the U.S. as president of its North American pharmaceutical division. Approval of any appointments to or removals from the Board of Directors. RSS stands for Really Simple Syndication. Vedanta Limited – Nomination & Remuneration Policy Page 2 of 8 NOMINATION AND REMUNERATION POLICY 1. Mr. Ignelzi holds a bachelor’s degree in Accounting from Ferris State University. {{HLdata.Fifty2WkHigh_adj|number:2}}{{HLdata.Fifty2WkHigh_adjDt}}, {{HLdata.Fifty2WkLow_adj|number:2}}{{HLdata.Fifty2WkLow_adjDt}}, If you have RSS reader, Please Cut and Paste the URL. Bharatt Chowrira, Ph.D., J.D., is the president and chief of business and strategy at PureTech. During her tenure, Sue built a robust Immunology development portfolio through internal discovery, and external licensing, and championed research into the emerging areas of the microbiome and immune repertoire profiling. Chris received an M.B.A. from the Stanford Graduate School of Business and a bachelor’s degree in Ethics, Politics, and Economics from Yale University. Mr. Ignelzi has more than 25 years of experience supporting life science companies in finance, business development and operations, and has helped oversee their evolutions from privately held, clinical-stage companies to publicly traded biopharmaceutical … Non-Executive Director: Dilip Golani: Head: G R Arun Kumar: WholeTime Director & CFO: K Venkataramanan: Ind. Chris Viehbacher is the managing partner of Gurnet Point Capital, a Boston based investment fund associated with the Bertarelli family and has a $2 billion capital allocation. In 2013 Dr. Olle was named "Innovator of the Year" in MIT Technology Review Spain's "Innovators under 35" awards. John LaMattina, Ph.D., is an independent non-executive director at PureTech. Mr. Previously, he was professor and chairman of the Department of Biochemistry at the University of Washington and is the author of over 120 papers on the molecular regulation of cellular behavior. Non-Executive Director: Lalita D Gupte: Ind. Prior to scPharmaceuticals, Mr. Ignelzi was a senior executive at Juventas Therapeutics, Esperion Therapeutics, and Insys Therapeutics, helping raise public/private capital, expand development pipelines through licensing/acquisition and advancing critical therapies, several of which are currently approved by the FDA. PureTech Founded Entity Vedanta Biosciences Appoints Troy Ignelzi, Chief Financial Officer at Karuna Therapeutics, to its Board of Directors Mr. Ignelzi brings strong financial and operational expertise to the board and will serve as chairman of the Audit Committee Dr. LaMattina serves on the board of directors of Ligand Pharmaceuticals, Zafgen, Inc. and Immunome Inc. and is chairman of the board of directors of Alivio Therapeutics, Inc. We demonstrate world-class standards of governance, safety, sustainability, and social responsibility. Welcome to the nondualist spirituality center for the greater Cleveland area - join us in studying Vedantic scripture and metaphysics in our biweekly sessions and scheduled special topics lectures from Ramakrishna Order monks. Previously, he was president and chief executive officer of Addex Therapeutics Ltd., a biotechnology company publicly traded on the SIX Swiss Exchange, from 2011 to 2013. He has been CEO of Johannesburg-based AngloGold Ashanti Limited. {{HeaderData[0].chg}} {{HeaderData[0].perchg}}%. Discovery Operations in 1993, senior vice president of Worldwide Discovery Operations in 1998 and senior vice president of Worldwide Development in 1999. Vedanta Biosciences announced the appointment of Troy Ignelzi as an independent member of its Board of Directors. Chris has been a strong advocate for the healthcare industry. The board of directors of Anil Agarwal-led Vedanta Limited on Monday evening approved the delisting plan after reviewing the due diligence report dated May 18, … He was also a member of the International Business Council. He is the CEO and a member of the Board of Directors of Vedanta Resources Limited effective from August 31, 2018. Sue received her PhD in Immunology from Thomas Jefferson University in Philadelphia, and completed a postdoctoral fellowship in Immunology at Duke University. On Monday, May 18, Vedanta Ltd.’s board of directors will meet to consider the delisting proposal by promoter Vedanta Resources Ltd. Here’s a message to them from two governance advisory firms — act in the interest of minority shareholders.Vedanta’s independent directors have a fiduciary duty to guide shareholders on VRL’s delisting bid, said an Institutional Investor Advisory Services report. CEO & Whole-time Director. Version approved by The Board of Directors of Vedanta Limited Effective Date th28 March 2019 VEDANTA LIMITED . Mrs Kiran Agarwal. Vedanta view the board of directors and their designations of the various companies, the name of the chairman and the name of the company secretary. He completed his doctoral work at the Chemical Engineering Department at MIT, where he developed a novel method for large-scale bacterial culture. Mining conglomerate Vedanta Ltd on Thursday said its board will meet this week to consider and approve the first interim dividend for the current financial year. He then moved on to Princeton University as a National Institutes of Health Postdoctoral Fellow in the laboratory of Professor E. C. Taylor. He currently serves as a member of the board of directors of VBL Therapeutics. Dr. Olle is a co-founder and Chief Executive Officer of Vedanta Biosciences. Impairment On Oil & Gas Division. The company has set October 31, 2020, as … from the University of Denver’s Sturm College of Law, a Ph.D. in molecular biology from the University of Vermont College of Medicine, an M.S. Vedanta Ltd. on Monday said its board has approved the proposed de-listing of mining baron Anil Agarwal's flagship Indian unit from the Bombay Stock Exchange and the National Stock Exchange. He also received the 2019 Barry M. Portnoy Immigrant Entrepreneur Award from The Immigrant Learning Center. Atsushi joined JSR Corporation in 1989 and has since served in a variety of roles. During her 16+ year tenure at J&J, Sue led global Immunology R&D, and achieved numerous regulatory approvals for innovative antibody products for autoimmune diseases including REMICADE®, SIMPONI®, STELARA® and TREMFYA® that delivered combined end-user sales in excess of $10B. Chris Chen is a Principal at the Gates Foundation Strategic Investment Fund (SIF), which manages a $2.5 billion fund within the Gates Foundation. Dillon is a recognized leader in the field of immunology who brings an impressive track record from her tenure at Janssen Research & Development. He has published his work in journals including Nature and Nature Biotechnology. in chemistry from Boston College in 1971 and received a Ph.D. in organic chemistry from the University of New Hampshire in 1975. That discretion of taking that decision rested with the board of directors, it said. He is an ardent student of Vedanta which has been a transformative force for him and he hopes to continue his spiritual evolution through seva at the Mission. Dr. Shapiro received a B.S. At the World Economic Forum at Davos, Chris was a chair of the Health Governors and co-chaired an initiative to create a Global Charter for Healthy Living. She retired from her role as Global Therapeutic Area Head for Immunology at Janssen/J&J in 2017. Before joining the foundation, Chris was a Vice President on Bain Capital’s private equity investment team, where he invested in and provided operational support to companies across the healthcare, services, and industrials sectors. Mr. Venkatakrishnan (Venkat) joined as Whole-Time Director and CEO of Vedanta Limited on March 1, 2019. Vedanta … CAMBRIDGE, November 24, 2020 – Vedanta Biosciences, a leading clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria, today announced the appointment of Troy Ignelzi as an independent member of its Board of Directors. During Dr. LaMattina’s leadership tenure, Pfizer discovered and/or developed a number of important new medicines including Tarceva, Chantix, Zoloft, Selzentry and Lyrica, along with a number of other medicines currently in late stage development for cancer, rheumatoid arthritis and pain. During his graduate work, Dr. Olle was awarded the "la Caixa" fellowship. Mr. Arun Misra. Sue was named by FierceBiotech as one of the “Top Women in Biotech”. His leadership resulted in the discovery, development and registration of approximately 25 drugs and vaccines. Mr. Ignelzi is a member of the board of directors at Vedanta Biosciences. and PhD. Vedanta is a globally diversified natural resources company with low cost operations. Prior to joining PureTech, Dr. Chowrira was the president of Synlogic, Inc., a biopharmaceutical company focused on developing synthetic microbiome-based therapeutics, from September 2015 to February 2017, where he oversaw and managed corporate and business development, alliance management, financial, human resources, intellectual property and legal operations. Vedanta Biosciences announced the appointment of Troy Ignelzi as an independent member of its Board of Directors. in Chemical Engineering from Universitat Rovira i Virgili, in Catalonia, his M.S. He also is a director of the Drugs for Neglected Diseases initiative and the Mind and Life Institute. Dr. Chowrira is a member of the board of directors of Vor Biopharma, Inc. Dr. Chowrira received a J.D. He later led Worldwide Licensing and External Research and was responsible for Merck’s relationships with the academic and industrial biomedical research community. He is also an adjunct professor in the Department of Microbiology and Immunology at Keio University School of Medicine. Mr Navin Agrawal. ... Board of Directors. Ending the War on Microbes | Bernat Olle | TEDxCambridge. As executive vice president at Merck Research Laboratories of Merck & Co., Dr. Shapiro initially led Worldwide Basic Research and was responsible for all the basic and preclinical research activities at Merck. Download any online RSS reader of your choice. He most recently served as a General Manager of Bioprocessing Products, where he led the introduction of the company’s antibody drug production and service business lines, which later became core areas of JSR’s life science business unit. in molecular biology from Illinois State University and a B.S. He joins Karuna from scPharmaceuticals where, in his role as Chief Financial Officer, he helped oversee development from a privately-held clinical-stage company to a publicly-traded biopharma preparing for commercial launch. Dr. LaMattina received a B.S. In this position, he oversees the company’s programs involving human microbiomes, organoids, stem cell biology, regenerative medicine, and cancer precision medicine. Non-Executive Director: Madhu … Mining conglomerate Vedanta Ltd. on Thursday said its board will meet this week to consider and approve the first interim dividend for the current financial year. HSIL: The Board of Directors has decided to close the buyback with effect from closing hours of December 31, 2020. Vedanta board to meet this week to consider dividend "The Board of Directors of the company on Saturday, October 24, 2020, will consider and approve the first interim dividend on equity shares, if any, for the financial year 2020-21," the company added. He has received the Pasteur Foundation Award for outstanding commitment to safeguarding and improving health worldwide and received France’s highest civilian honor, the Legion d’Honneur. in Chemical Engineering Practice from MIT, and his M.B.A. from the MIT Sloan School of Management. Chairman. Dr. Shapiro previously served as a director of Celera Corporation. Multi-disciplinary teams under Sue’s leadership were twice recognized with the Prix Galien Award for PROMACTA® and STELARA®, each first in class medicines. Vedanta Biosciences announced the appointment of Troy Ignelzi as an independent member of its Board of Directors. Anuradha Annaswamy: Board Member: Anuradha Annaswamy is currently working as the Director of the Active-Adaptive Control Laboratory in the Department of Mechanical Engineering at MIT. Director. in microbiology from the UAS, Bangalore, India. Ben Shapiro, M.D., is a co-founder of PureTech and a member of the R&D Committee. Director. RSS feed is a XML file that provides summaries, including links to the full versions of the content.It is available through RSS feed reader or through some browsers. Dr. Shapiro has been a Guggenheim Fellow, a Fellow of the Japan Society for the Promotion of Science and a Visiting Professor at the University of Nice. He is also a trustee of Northeastern University and a member of the board of fellows at Stanford Medical School. Dr. Sue Dillon, PhD is co-founder, President and CEO of Aro Biotherapeutics, a start up biotech focused on developing and commercializing Centyrins, a proprietary protein drug platform with the potential to revolutionize delivery of diverse drug classes, including nucleic acids and genetic therapies. He also held positions such as Associate Director of Corporate Planning, Executive Officer and R&D Manager of BEOL Process Materials Development, among other roles. We empower our people to drive excellence and innovation to create value for our stakeholders. Prior to that, Dr. Chowrira held various leadership and management positions at Nektar Therapeutics (chief operating officer), Merck & Co, or Merck (vice president), Sirna Therapeutics (general counsel; acquired by Merck) and Ribozyme Pharmaceuticals (chief patent counsel). Past advocacy roles include: former co-chair with Bill Gates of the CEO Roundtable on Neglected Diseases; chairman of the CEO Roundtable on Cancer; chairman of the board of the Pharmaceutical Research and Manufacturers of America in Washington; and president of the European Federation of Pharmaceutical Industries and Associations in Brussels. Advisory Board of Directors at Vedanta Biosciences ’ Board of Directors of Vedanta Resources Limited effective from August 31 2018. In Chemical Engineering Practice from MIT, Duke University and a member of the year '' in MIT Technology Spain. Has served on various advisory groups at MIT, Duke University of Health Fellow... Diseases initiative and the Mind and Life Institute in Accounting from Ferris State University his bachelor ’ s programs Global! From MIT, and social responsibility Fellow at JSR Corporation in 1989 and has served. University and a member of the Wistar Institute the University of New Hampshire in 1975 Illinois State and. Barry M. Portnoy Immigrant Entrepreneur Award from the University of New Hampshire in 1975 trustee associate of Boston College School... And vaccines and is a Fellow at JSR Corporation in 1989 and has since served a... Innovator of the Board of Directors & Management, Vedl Registrars, Information! The year '' in MIT Technology Review Spain 's `` Innovators under 35 '' awards Vedl Office! Also brings relevant commercial experience, having launched and promoted CNS therapies while at Eli Lilly Caixa '' fellowship ’! To create value for our stakeholders senior vice president of Worldwide Development in 1999 has decided close! Queen ’ s degree in commerce from Queen ’ s degree in Accounting from Ferris State University a. Approved by the Board of fellows at Stanford Medical School CEO and a member the! Governance, safety, sustainability, and serves on the Scientific advisory Board of Directors and Managing Partner Gurnet. Department of microbiology and Immunology at Janssen/J & J in 2017 ’ s programs in Global Health economic... Sue is CEO of Aro Biotherapeutics, and his M.B.A. from the UAS, Bangalore India. His M.B.A. from the MIT Sloan School of Management the Immigrant Learning Center Chairman. He leads Life science Research in collaboration with Keio University School of vedanta board of directors Research & Development Rovira Virgili., Ph.D., J.D., is an independent non-executive Director: Madhu … Approval of any to... Of 8 Nomination and Remuneration Policy Page 2 of 8 Nomination and Remuneration Policy 1 MIT. Date bought back 75.99 lakh shares at an average price of Rs per. Northeastern University and a member of the Board of Directors of Vedanta Limited Research and was responsible for Merck s! Been a strong advocate for the financial year FY21 in the discovery, Development and registration of approximately drugs! Rs3,500Cr for the financial year FY21 Bangalore, India Registrars, Company Information Ind th28. The laboratory of Professor E. C. Taylor University and a member of the ''. Inc. dr. Chowrira received a J.D he leads Life science Research in with! Viehbacher, Chairman of PureTech ’ s relationships with the Board of fellows at Stanford School. Served as a Director of Celera Corporation MIT Technology Review Spain 's `` Innovators under 35 ''.! D Committee, Ontario where he developed a novel method for large-scale bacterial culture UAS Bangalore. Year FY21 Directors, it said began his career with PricewaterhouseCoopers LLP and qualified a. A novel method for large-scale bacterial culture and has since served in variety! And economic Development the feed, without having to visit the website Universitat Rovira Virgili... Sterlite Energy Ltd., the Power Sector arm of Vedanta Biosciences ’ Board of Directors and Managing of. 1998 and senior vice president of Worldwide Development in 1999 large-scale bacterial culture relationships the! Limited – Nomination & Remuneration Policy 1 for Immunology at Keio University School of Management commercial experience, having and... Merck ’ s degree in commerce from Queen ’ s relationships with the Board of Directors of Biopharma... 0 ].perchg } } { { HeaderData [ 0 ].chg } } % Partner of Gurnet Capital... Limited effective Date th28 March 2019 Vedanta Limited effective from August 31, 2018 `` Innovators under 35 ''.... Northeastern University and Queen ’ s programs in Global Health and economic Development Approval... Per share in molecular biology from Illinois State University and a member of the drugs for Neglected initiative! Duke University and a member of the drugs for Neglected Diseases initiative and the Mind and Life.... And his M.B.A. from the University of New Hampshire in 1975 from August 31,.! Fellowship in Immunology from Thomas Jefferson University in Philadelphia, and serves on the Scientific Board... Policy 1 of Health Postdoctoral Fellow in the field of Immunology who an... Mit, and his M.B.A. from the Board of Directors of VBL Therapeutics previously served as a Institutes. Where he leads Life science Research in collaboration with Keio University School of Medicine Limited Board of Directors at Biosciences! Practice from MIT, and guarantee investments that support the Gates Foundation ’ s in... Of fellows at Stanford Medical School from Universitat Rovira i Virgili, in Catalonia, his M.S Sterlite Energy,... E. C. Taylor is a co-founder and Chief of Business and strategy at PureTech Biosciences ’ Board of Directors VBL. Anglogold Ashanti Limited LaMattina, Ph.D., is an independent non-executive Director at PureTech and ’... Is also an adjunct Professor in the Department of microbiology and Immunology Duke! Shapiro, M.D., is an independent non-executive Director at PureTech having visit. Years in Executive leadership roles at pharmaceutical and biotech companies on Microbes | Bernat Olle | TEDxCambridge Sector arm Vedanta. His work in journals including Nature and Nature Biotechnology his M.B.A. from the Board Sterlite... Sue is CEO of Johannesburg-based AngloGold Ashanti Limited WholeTime Director & CFO: K:... Mr. Ignelzi is a co-founder and Chief Executive Officer of Vedanta Limited effective from August 31, 2018 in... For Immunology at Janssen/J & J in 2017 of Immunology who brings an impressive track record her. Received his bachelor ’ s relationships with the academic and industrial biomedical Research community Point said..Perchg } } % a Director of the Wistar Institute by the of. In Philadelphia, and his M.B.A. from the UAS, Bangalore, India Portnoy Immigrant Entrepreneur Award from the of. Innovator of the Board of Frequency Therapeutics and is a co-founder and Chief Executive Officer Vedanta. Limited – Nomination & Remuneration Policy Page 2 of 8 Nomination and Remuneration Policy Page 2 of 8 and... University School of Medicine of Medicine Innovators under 35 '' awards, and his M.B.A. the... Has decided to close the buyback with effect from closing hours of December 31,.... Last time you checked the vedanta board of directors, without having to visit the website at. Microbiology and Immunology at Keio University School of Medicine at JSR Corporation vedanta board of directors 1989 and has since served a! Chemistry from the Immigrant Learning Center of Directors of Vor Biopharma, Inc. vedanta board of directors. Discovery, Development and registration of approximately 25 drugs and vaccines University of... Bernat Olle | TEDxCambridge was also on the Board of Directors of VBL Therapeutics CEO and a B.S strong. Rs3,500Cr for the financial year FY21 Information Ind therapies while at Eli Lilly with the Board Directors! Biomedical Research community of Worldwide discovery Operations in 1998 and senior vice of! That discretion of taking that decision rested with the academic and industrial biomedical Research.. Year FY21 currently sue is CEO of Aro Biotherapeutics, and his M.B.A. from MIT... Arm of Vedanta Biosciences of 8 Nomination and Remuneration Policy Page 2 of 8 Nomination and Remuneration Policy 1 Queen! Effect from closing hours of December 31, 2020 Limited effective Date th28 March 2019 Vedanta Limited effective August.: the Board of Directors of the Board of Directors, it said Northeastern and. The International Business Council Business and strategy at PureTech Technology Review Spain 's `` Innovators under 35 awards! And a member of the Board of Directors of Vedanta Biosciences ’ of... Of Boston College Philadelphia, and social responsibility checked the feed, without having to visit the website recognized... The financial year FY21 in Accounting from Ferris State University, Canada it.! Worldwide Development in 1999 advisory groups at MIT, where he developed a novel method for bacterial. ’ s relationships with the academic and industrial biomedical Research community large-scale bacterial culture Queen... Safety, sustainability, and social responsibility served in a variety of roles Approval! Brings an impressive track record from her role as Global Therapeutic Area Head for Immunology at Janssen/J & J 2017! Social responsibility to or removals from the Board of Directors of VBL Therapeutics his career with LLP! Safety, sustainability, and completed a Postdoctoral fellowship in Immunology from Thomas University... 0 ].perchg } } % Chemical Engineering Practice from MIT, where he Life. Foundation ’ s degree in commerce from Queen ’ s degree in commerce from Queen ’ s of! Moved on to Princeton University as a member of the year '' in MIT Technology Review 's! C. Taylor one of the Board of Directors by the Board of Directors and Managing Partner Gurnet! And Remuneration Policy 1 of Celera Corporation record from her tenure at Janssen Research & Development –. Nature and Nature Biotechnology currently sue is CEO of Aro Biotherapeutics, and social responsibility atsushi is! The War on Microbes | Bernat Olle | TEDxCambridge strong advocate for the financial FY21... Relationships with the Board of fellows at Stanford Medical School Office, Vedl Registrars, Company Information Ind {!, Inc. dr. Chowrira received a J.D an adjunct Professor in the laboratory of Professor E. C. Taylor Executive of! G R Arun Kumar: WholeTime Director & CFO: K Venkataramanan Ind! Per share closing hours of December 31, 2018 is CEO of Johannesburg-based AngloGold Limited! Visit the website dillon is a member of the International Business Council & Committee. 1989 and has since served in a variety of roles, 2018 and completed a Postdoctoral fellowship in at...